Another window into tumor microenvironment: a case of Β‐cell rich folliculotropic mycosis fungoides responding to rituximab

Nikolaou, Vasiliki; Iliakis, Theodoros; Marinos, Leonidas; Voudouri, Dimitra; Sidiropoulou, Polytimi; Rigopoulos, Dimitrios; Stratigos, Alexander J.

doi:10.1111/ajd.13217

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preclinical data indicate that B cells may exert a pro-tumourigenic effect by their ability to promote an immunosuppressive milieu through releasing factors that promote tumour growth ( 33 ). Notably, 2 patients with FMF showing significant B-cell infiltrates were treated with either intralesional or systemic rituximab and experienced a sustained remission, suggesting that local depletion of B cells can re-establish immunological tumour control ( 32 , 34 ).…”

Section: Discussionmentioning

confidence: 99%

Stage-dependent Increase in Expression of miR-155 and Ki-67 and Number of Tumour-associated Inflammatory Cells in Folliculotropic Mycosis Fungoides

Atzmony¹,

Moyal²,

Feinmesser³

et al. 2020

Acta Derm Venereol

View full text Add to dashboard Cite

Folliculotropic mycosis fungoides, the most common variant of mycosis fungoides, was recently suggested to present with 2 distinct stages: early-stage and advanced/tumour-stage, each with different prognostic implications. To gain further insight into the different presentations of folliculotropic mycosis fungoides, skin biopsies of folliculotropic mycosis fungoides were studied for miR-155 expression, a well-documented cancer promoter in classic mycosis fungoides, the proliferation marker Ki-67 expression, and the composition of the inflammatory infiltrate. This study shows that, similar to classic mycosis fungoides, expression of miR-155, dermal Ki-67 immunoreactivity, and the number of tumour-infiltrating B-cells and macrophages are also increased in a stage-dependent manner in folliculotropic mycosis fungoides. Recent studies suggest that folliculotropic mycosis fungoides (FMF), the most common variant of mycosis fungoides (MF), presents with 2 distinct clinicopathological stages: early indolent stage and more aggressive advanced/tumour stage. To further characterize these stages, miR-155 expression was studied with qRT-PCR and found to be significantly higher in biopsies of tumour-stage FMF compared with early-stage FMF and inflammatory dermatoses. There was no statistically significant difference in miR-155 expression between early-stage FMF and early-stage MF, nor between tumour-stage FMF and tumour-stage MF. Immunohistochemical analysis revealed a significantly increased number of dermal Ki-67 + proliferating lymphocytes in tumour-stage FMF, together with an increased number of CD20 + B cells and CD68 + macrophages compared with early-stage FMF. Thus, similar to classic MF, miR-155, Ki-67 tumour cell immunoreactivity, and certain tumour-infiltrating inflammatory cells are differentially expressed in early-vs tumour-stage FMF. The results of this study corroborate the notion that FMF presents with 2 distinct stages.

show abstract

Section: Discussionmentioning

confidence: 99%

Stage-dependent Increase in Expression of miR-155 and Ki-67 and Number of Tumour-associated Inflammatory Cells in Folliculotropic Mycosis Fungoides

Atzmony¹,

Moyal²,

Feinmesser³

et al. 2020

Acta Derm Venereol

View full text Add to dashboard Cite

show abstract

“…Their conclusion was that the decrease in IL-10producing Bregs may play an important role in MF progression. Some case reports of MF patients with the CD20+ phenotype with a good response to rituximab (an anti-CD20 monoclonal antibody) are available in the literature [41,42], suggesting that Bregs may play a role in MF progression and encouraging further studies to shed light on their role.…”

Section: Brigs In Mfmentioning

confidence: 99%

The Microenvironment’s Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications

Pileri

Guglielmo

Grandi

et al. 2021

Cells

View full text Add to dashboard Cite

Background: Mycosis fungoides (MF) and Sezary Syndrome (SS) are the most common cutaneous T-cell lymphomas. It has been hypothesized that the interaction between the immune system, cutaneous cells, and neoplastic elements may play a role in MF/SS pathogenesis and progression. Methods: This paper aims to revise in a narrative way our current knowledge of the microenvironment’s role in MF/SS. Results and Conclusions: Literature data support a possible implication of microenvironment cells in MF/SS pathogenesis and progression, opening up new therapeutic avenues.

show abstract

Cutaneous T cell lymphoma atlas reveals malignant TH2 cells supported by a B cell-rich tumor microenvironment

Li,

Strobl,

Poyner

et al. 2024

Nat Immunol

View full text Add to dashboard Cite

Cutaneous T cell lymphoma (CTCL) is a potentially fatal clonal malignancy of T cells primarily affecting the skin. The most common form of CTCL, mycosis fungoides, can be difficult to diagnose, resulting in treatment delay. We performed single-cell and spatial transcriptomics analysis of skin from patients with mycosis fungoides-type CTCL and an integrated comparative analysis with human skin cell atlas datasets from healthy and inflamed skin. We revealed the co-optation of T helper 2 (TH2) cell-immune gene programs by malignant CTCL cells and modeling of the tumor microenvironment to support their survival. We identified MHC-II+ fibroblasts and dendritic cells that can maintain TH2 cell-like tumor cells. CTCL tumor cells are spatially associated with B cells, forming tertiary lymphoid structure-like aggregates. Finally, we validated the enrichment of B cells in CTCL and its association with disease progression across three independent patient cohorts. Our findings provide diagnostic aids, potential biomarkers for disease staging and therapeutic strategies for CTCL.

show abstract

Another window into tumor microenvironment: a case of Β‐cell rich folliculotropic mycosis fungoides responding to rituximab

Cited by 3 publications

References 9 publications

Stage-dependent Increase in Expression of miR-155 and Ki-67 and Number of Tumour-associated Inflammatory Cells in Folliculotropic Mycosis Fungoides

Stage-dependent Increase in Expression of miR-155 and Ki-67 and Number of Tumour-associated Inflammatory Cells in Folliculotropic Mycosis Fungoides

The Microenvironment’s Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications

Cutaneous T cell lymphoma atlas reveals malignant TH2 cells supported by a B cell-rich tumor microenvironment

Contact Info

Product

Resources

About